Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

31 Jan 2013

Abstract excerpt

The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene signature, which result was available for 427 patients (cT1-3N0M0). Adjuvant systemic treatment decisions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Breast Lesions and Carcinomas
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23371464
DOI: 10.1002/ijc.28082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyPMID 23371464Read ↗

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read ↗

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.Semantic proximity Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerSemantic proximity Read ↗

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of ageSemantic proximity Read ↗

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation studySemantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity Read ↗

Clinically relevant gene signatures provide independent prognostic information in older breast cancer patientsSemantic proximity Read ↗

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER statusSemantic proximity Read ↗

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.